William Blair analyst Matt Phipps has reiterated their bullish stance on UPB stock, giving a Buy rating on March 12.
Matt Phipps’s rating is based on several compelling factors that highlight Upstream Bio, Inc.’s promising outlook. The company has shown strong execution in its ongoing Phase II trials for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and is on track to begin a Phase II trial for chronic obstructive pulmonary disease (COPD) later this year. The recent Phase III results for Tezspire in CRSwNP set a benchmark that Upstream’s drug, verekitug, aims to meet or exceed with its dosing regimen, which could significantly impact the company’s stock performance.
Additionally, Upstream Bio has positioned verekitug as a differentiated product within the TSLP class, focusing on its potency advantages and potential for longer dosing intervals. This strategic positioning, coupled with the use of registration-enabling primary endpoints in Phase II trials, suggests a streamlined path to regulatory approval, potentially reducing costs and time. These factors, along with the anticipation of further data releases, underpin Phipps’s Buy rating for the stock.